Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Stage

Acquired | Acquired

About Lineage Biosciences

Lineage Biosciences was founded based on technology for the profiling of antibody responses using next-generation sequencing of immunoglobulin genes (Ig-SEQ). Ig-SEQ enables deep analysis of antibodies generated by natural immune responses during infection, autoimmune disease, cancer, immunization, and vaccination.

Lineage Biosciences Headquarter Location

Palo Alto, California,

United States

Latest Lineage Biosciences News

AbCellera Acquires Lineage Biosciences

Aug 1, 2018

August 01, 2018 06:07 AM Eastern Daylight Time VANCOUVER, British Columbia--( BUSINESS WIRE )--AbCellera Biologics Inc., a technology leader in therapeutic antibody discovery, has acquired Lineage Biosciences in an all-stock transaction. Through the acquisition, AbCellera expands its capabilities in antibody discovery and vaccine research by obtaining exclusive rights to foundational technology for immune repertoire sequencing. Lineage Biosciences, a Palo Alto-based start-up, was founded based on technology for the profiling of antibody responses using next-generation sequencing of immunoglobulin genes (Ig-SEQ). Ig-SEQ enables deep analysis of antibodies generated by natural immune responses during infection, autoimmune disease, cancer, immunization, and vaccination. Ig-SEQ was developed by Professor Stephen Quake’s research group at Stanford University, which licenses the technology to Lineage Biosciences. Ig-SEQ has been widely adopted as a platform for basic and translational immunology research and is increasingly being applied in industry to develop vaccines and to accelerate antibody discovery. Deep profiling of antibody repertoires complements the unique functional information obtained from AbCellera’s single B cell discovery platform, increasing the diversity of antibodies identified and enabling comprehensive analysis of immune responses over time. “Through this acquisition, AbCellera has expanded its intellectual property estate into an important area. The addition of repertoire sequencing is strategic and complements our core microfluidic single-cell screening platform. It reinforces our technology advantage in antibody discovery and vaccine research,” commented Dr. Carl Hansen, CEO of AbCellera. About AbCellera Biologics Inc. AbCellera is a privately held company that engages in partnerships to discover and develop next-generation therapeutic antibodies. AbCellera’s single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation. Ultra-deep screening of single B cells allows unprecedented access to natural immune responses, enabling rapid isolation of large and diverse panels of high-quality lead antibodies from any species, including humans. www.abcellera.com Find a complete list of news announcements on AbCellera’s online news feed , on LinkedIn and on Twitter @AbCelleraBio .

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lineage Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lineage Biosciences is included in 1 Expert Collection, including Cancer.

C

Cancer

4,844 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Lineage Biosciences Patents

Lineage Biosciences has filed 5 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Immunology
  • Analytical chemistry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/23/2018

7/28/2020

Molecular biology, Biotechnology, Olfactory receptors, DNA, Genetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

7/23/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/28/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Biotechnology, Olfactory receptors, DNA, Genetics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.